SELLAS Life Sciences (SLS) Long-Term Deferred Tax (2011 - 2016)

SELLAS Life Sciences (SLS) has 6 years of Long-Term Deferred Tax data on file, last reported at -$5.7 million in Q4 2016.

• Quarterly Long-Term Deferred Tax fell 4.49% year-over-year to -$5.7 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$5.7 million (down 4.49% YoY) and the FY2016 annual result came in at -$5.7 million, down 4.49% from the prior year.
• Long-Term Deferred Tax fell to -$5.7 million in Q4 2016 per SLS's latest filing, from -$5.4 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at -$5.1 million in Q1 2012 and bottomed at -$5.7 million in Q4 2016.
• The 5-year median for Long-Term Deferred Tax is -$5.1 million (2012), against an average of -$5.1 million.
• The widest annual swing landed in 2012, when Long-Term Deferred Tax changed 0.0%; it then decreased 7.22% in 2015.
• Tracing SLS's Long-Term Deferred Tax over 5 years: stood at -$5.1 million in 2012, then changed by 0.0% to -$5.1 million in 2013, then changed by 0.0% to -$5.1 million in 2014, then dropped by 7.22% to -$5.4 million in 2015, then retreated by 4.49% to -$5.7 million in 2016.
• Per Business Quant, the three latest SLS Long-Term Deferred Tax figures stand at -$5.7 million (Q4 2016), -$5.4 million (Q4 2015), and -$5.1 million (Q3 2015).

Peer Comparison